HRS 6209
Alternative Names: HRS-6209Latest Information Update: 04 Dec 2023
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Antineoplastics
- Mechanism of Action Cyclin-dependent kinase 4 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 04 Dec 2023 Phase-I clinical trials in Solid tumours (Late-stage disease) (unspecified route), prior to December 2023 (Jiangsu HengRui Medicine pipeline, December 2023)
- 30 Mar 2023 Jiangsu Hengrui Medicine plans a phase I trial for solid tumours (Late-stage disease) in China in April 2023 (NCT05781048)
- 30 Mar 2023 Preclinical trials in Solid tumours in China (NCT05781048)